Free Radicals, Oxidative Stress, and Antioxidants in Human Health and Disease

Okezie I. Aruoma*

OICA International, Saint Lucia, West Indies, and Pharmacology Group, King’s College London, London SW3 6LX, Great Britain

ABSTRACT: Free radicals and other reactive oxygen species (ROS) are constantly formed in the human body. Free-radical mechanisms have been implicated in the pathology of several human diseases, including cancer, atherosclerosis, malaria, and rheumatoid arthritis and neurodegenerative diseases. For example, the superoxide radical (O$_2^-$) and hydrogen peroxide (H$_2$O$_2$) are known to be generated in the brain and nervous system in vivo, and several areas of the human brain are rich in iron, which appears to be easily mobilizable in a form that can stimulate free-radical reactions. Antioxidant defenses to remove O$_2^-$ and H$_2$O$_2$ exist. Superoxide dismutases (SOD) remove O$_2^-$ by greatly accelerating its conversion to H$_2$O$_2$. Catalases in peroxisomes convert H$_2$O$_2$ into water and O$_2$ and help to dispose of H$_2$O$_2$ generated by the action of the oxidase enzymes that are located in these organelles. Other important H$_2$O$_2$-removing enzymes in human cells are the glutathione peroxidases. When produced in excess, ROS can cause tissue injury. However, tissue injury can itself cause ROS generation (e.g., by causing activation of phagocytes or releasing transition metal ions from damaged cells), which may (or may not, depending on the situation) contribute to a worsening of the injury. Assessment of oxidative damage to biomolecules by means of emerging technologies based on products of oxidative damage to DNA (e.g., 8-hydroxydeoxyguanosine), lipids (e.g., isoprostanes), and proteins (altered amino acids) would not only advance our understanding of the underlying mechanisms but also facilitate supplementation and intervention studies designed and conducted to test antioxidant efficacy in human health and disease.

JAOCs 75, 199–212 (1998).

KEY WORDS: Antioxidants, atherosclerosis, DNA damage, flavonoids, free radicals, 8-hydroxydeoxyguanosine, isoprostanes, lipid peroxidation, oxidative protein damage, oxidative stress, phytochemicals.

Humans and other aerobes are able to tolerate oxygen (O$_2$) because, at the same time that organisms were evolving electron transport chains and other enzyme systems to use it, antioxidant defenses to protect against the toxic effects of O$_2$ were evolving in parallel. The predecessors of the anaerobic bacteria that exist today followed the “blind” evolutionary path of restricting themselves to environments that O$_2$ did not penetrate. Hence, the evolution of multicellular aerobes and of antioxidant defense mechanisms is intimately related.

Interest in free radicals began with the work of Moses Gomberg (1), who in 1900 demonstrated the existence of the triphenylmethyl radical (Ph$_3$C·). A free radical is any chemical species (capable of independent existence) that possesses one or more unpaired electrons, an unpaired electron being one that is alone in an orbital. Radicals are generally less stable than nonradicals, although their reactivities vary. The simplest free radical is an atom of the element hydrogen. The hydrogen atom contains one proton and a single unpaired electron, which qualifies it as a free radical—often denoted by the insertion of the radical dot (·) to indicate that one or more unpaired electrons is present.

Once radicals form, they can react either with another radical or with another molecule by various interactions. The rate and selectivity of these types of reactions depend on high concentrations of the radicals, on delocalization of the single electron of the radical (thus increasing its life time), and on the absence of weak bonds in any other molecules present with which the radical could interact (see Table 1). Most biological molecules are nonradicals that contain only paired electrons. Extensive discussions on free-radical chemistry may be found elsewhere (2–7).

Gerschman et al. (8) proposed that “oxygen poisoning and radiation injury have at least one common basis of action, possibly the formation of oxidizing free radicals.” This pioneering idea soon began to capture the imaginations of scientists. In the early 1960s, superoxide was found to be associated with a number of enzymes, including xanthine oxidase. However, it was believed that this free radical was “bound” to the enzyme. In 1968, it was discovered that superoxide was secreted into solution (9–11), allowing superoxide to mediate cellular toxicity.

The role of free-radical reactions in human disease, biology, toxicology, and the deterioration of food has become an area of intense interest. In the main, the free-radical reaction of lipid peroxidation is an important issue in the food industry where manufacturers minimize oxidation in lipid-containing foods by use of antioxidants during the manufacturing process; foods are produced that maintain their nutritional quality over a defined shelf life. By contrast, biomedical sci-
entists and clinicians are interested in antioxidants because they protect the body against damage by reactive oxygen species (11–21). The rest of this article will focus on biomedical aspects of free radicals.

**REACTIVE OXYGEN SPECIES**

Free radicals of importance in living organisms include hydroxyl (OH·), superoxide (O₂⁻), nitric oxide (NO·), and peroxyl (RO₂·). Peroxynitrite (ONOO⁻), hypochlorous acid (HOCℓ), hydrogen peroxide (H₂O₂), singlet oxygen \(^1\Delta g\) (often written as \(^1\text{O}_2\)), and ozone \((\text{O}_3)\) are not free radicals but can easily lead to free-radical reactions in living organisms. The term “reactive oxygen species” (ROS) is often used to include not only the radicals OH·, RO₂·, NO· and O₂⁻ but also the nonradicals HOCℓ, \(\text{O}_2\), ONOO⁻, \(\text{O}_3\), and H₂O₂.

Extensive reviews on the role of free radicals in biology and medicine abound (22–30). Scheme 1 summarizes the mechanisms of cellular damage in oxidative stress. “Oxidative stress” is the term that refers to the imbalance between...
generation of ROS and the activity of the antioxidant defenses. Severe oxidative stress can cause cell damage and death. It has been implicated in numerous human diseases (Table 2). In mammalian cells, oxidative stress appears to lead to increases in the levels of free Ca\(^{2+}\) and iron within cells (31,32). Indeed, Orrenius et al. (31) have suggested that excessive rises in intracellular free Ca\(^{2+}\) may cause DNA fragmentation by activating endonucleases. The importance of oxidative stress injury depends on the molecular target, the severity of the stress, and the mechanism by which the oxidative stress is imposed, i.e., drug-induced, Fenton chemistry, trauma, enzyme activation [e.g., NO· synthase (NOS) activity], etc. Brief comments on some of the ROS are worthwhile.

**Ozone.** This pale blue gas, which is not produced in vivo, serves as an important protective shield against solar radiation in the atmosphere. Close to the earth’s surface, O\(_3\) is an unwanted oxidant and is often regarded as the most toxic air pollutant (33). O\(_3\) can form in laboratory equipment that has high-energy ultraviolet (UV)-producing lamps and in urban air as a result of photochemical reactions and pollution. The tissue most susceptible to damage upon exposure to O\(_3\) is the lung. The biological effect of O\(_3\) is often attributed to its ability to cause oxidation or peroxidation of biomolecules either directly or via free-radical mechanisms (34–36).

**Nitric oxide (NO).** NO· is a free radical. It is widely thought that the endothelium-derived relaxing factor (EDRF) produced by vascular endothelium, which is an important mediator of vascular responses induced by several pharmacological agents (including bradykinin and acetylcholine), is identical to NO· (37,39). Vascular endothelial cells that line the blood vessels also seem to produce small amounts of O\(_2^-\), some of which could react with NO to produce nonradical...
products. Thus, variation in the production of NO· and O₂⁻ by endothelium might provide one mechanism for the regulation of vascular tone and hence blood pressure.

A role for NO· has also been demonstrated in such human diseases as malaria, where NO· appears to be partly involved in resistance to malaria infection, in cardiovascular disease, acute inflammation, cancer, neurodegenerative diseases, and diabetes. NO· exerts potent actions in the regulation of cell function and tissue viability—this includes the recognized ability to mediate signal transduction via stimulation of guanylate cyclase-mediated cGMP synthesis (reviewed in Refs. 37–43). Sessa et al. (44) advocated that in dogs, “chronic exercise, presumably by increasing endothelial shear stress, increases EDRF/NO· production and endothelial cell NO· synthase gene expression, and may contribute to the beneficial effects of exercise on the cardiovascular effort.” The reaction between NO· and O₂⁻ leads to DNA oxidative damage owing to the formation of ONOO⁻, which may have OH·-like potential, leading to the formation of nitroguanine and other loose products (45–51). ONOO⁻ has the propensity to damage supercoiled DNA in plasmid pBR322 (52). A suggested toxicity of NO· involves its reaction with O₂⁻ to give ONOO⁻, a reaction that occurs with a rate constant of 6.7 × 10⁹ M⁻¹s⁻¹ (53). ONOO⁻ has been suggested to mediate NO-dependent toxicity. In addition to DNA base nitration mentioned above, ONOO⁻ potentiates the activation of guanylate cyclase; has bactericidal activity and trypanocidal activity, converting low-density lipoprotein (LDL) to a form that may be recognized by the macrophage scavenger receptor; induces peroxidation of lipids; oxidizes methionine and SH residues in proteins; depletes antioxidants (e.g., ascorbate, glutathione), nitrates tyrosine residues; and inactivates α₁-antiprotease (α₁AP) (the major inhibitor of serine proteases in human body fluids). Indeed, nitration of tyrosine residues appears to be a “marker” of ONOO⁻-dependent damage in vivo (42,54–63).

Peroxyl radicals (RO₂⁻). These radicals are intermediate species formed during lipid oxidation chain reactions, such as the oxidation of polyunsaturated fats, resulting in deterioration of lipid-containing foods. Lipid peroxidation may be ini-

### TABLE 2

Some Clinical Conditions in Which Free Radicals and Other Reactive Oxygen Species Are Thought to Be Involved

| Condition                                      | Condition                                      |
|-----------------------------------------------|-----------------------------------------------|
| BRAIN                                         | INFLAMMATORY IMMUNE INJURY                     |
| Parkinson’s disease                           | Rheumatoid arthritis                           |
| Neurotoxins                                   | Glomerulonephritis                             |
| Vitamin E deficiency                          | Autoimmune diseases (HIV/AIDS)                 |
| Hyperbaric oxygen                             | Vasculitis (hepatitis B virus)                 |
| Hypertensive cerebrovascular injury           | ALCOHOLISM                                     |
| Aluminum overload                             | AGING                                         |
| Allergic encephalomyelitis (demyelinating diseases) | Age-related macular degeneration               |
| Potentiation of traumatic injury              | RADIATION INJURY                                |
| EYE                                           | IRON OVERLOAD                                   |
| Photic retinopathy                            | Nutritional deficiencies (kwashiorkor)         |
| Occular hemorrhage                            | Thalassemia and other chronic anemias treated  |
| Cataractogenesis                              | with multiple blood transfusions               |
| Degenerative retinal damage                   | Dietary iron overload (red wine, beer brewed in |
| Retinopathy of prematurity                    | iron pots)                                     |
| HEART AND CARDIOVASCULAR SYSTEM               | Idiopathic hemochromatosis                      |
| Atherosclerosis                               | RED BLOOD CELLS                                 |
| Adriamycin cardiotoxicity                     | Fanconi’s anemia                                |
| Keshan disease (selenium deficiency)          | Sickle cell anemia                              |
| Alcohol cardiomyopathy                        | Favism                                         |
| KIDNEY                                        | Malaria                                        |
| Metal ion-mediated nephrotoxicity             | Protoporphyrin photo-oxidation                 |
| Aminoglycoside nephrotoxicity                 | LUNG                                           |
| Autoimmune nephritic syndromes               | Bronchopulmonary dysplasia                      |
| GASTROINTESTINAL TRACT                        | Mineral dust pneumocnosis                       |
| NSAID-induced GI tract lesions⁶              | Bleomycin toxicity                              |
| Oral iron poisoning                           | Hypoxia                                        |
| Endotoxin liver injury                        | Cigarette smoke effect                         |
| Diabetogenic actions of alloxan              | Emphysema                                      |
| Halogenated hydrocarbon liver injury          | ARDS (some forms)                               |
| FFA-induced pancreatitis                      | Oxidant pollutants (O₃, SO₂, NO₂)              |
| CANCER                                        | ISCHEMIA-REPERFUSION                            |
|                                              | Stroke/myocardial infarction                    |
|                                              | Organ transplantation                           |
|                                              | AMIOTROPHIC LATERAL SCLEROSIS                   |

⁶Abbreviations: ARDS, adult respiratory distress syndrome; NSAID, nonsteroidal antiinflammatory drug; FFA, free fatty acid.

⁶Skin injury due to solar radiation, porphyria, contact dermatitis, and photosensitizers may also involve free-radical mechanisms.
tiated by any species that has sufficient reactivity to abstract a hydrogen atom from a polyunsaturated fatty acid (PUFA) side chain (such as those of arachidonic acid and linolenic acid, for example) in membrane lipids. Arachidonic acid is a precursor of prostaglandins and leukotrienes. It contains a number of methylene-interrupted double bonds, which are particularly prone to hydrogen atom abstraction (64). Although much has been written about the mechanism and biological significance of lipid peroxidation, there seems to be no unanimity in the methods for its measurement. Delineation of lipid peroxidation as a major pathway in most degenerative diseases (Table 2) would depend on adequate standardization and control of measurement conditions. The link between DNA damage, faulty repair of DNA, proto-oncogene activation, and the ability of some of the end-products of lipid peroxidation to act as promoters of carcinogenesis is widely discussed (65,66).

End-products of lipid peroxidation could have profound effects on vascular function because of their ability to mimic or antagonize the actions of some of the stereospecific products formed by cyclooxygenase and lipoxygenase enzymes. For example, the F2-isoprostanes are generated by the peroxidation of arachidonic acid via the generation of RO2· isomers, which undergo endocyclization to prostaglandin-like compounds. Their formation in vivo appears to be enhanced under conditions of oxidative stress, such as smoking, exposure to xenobiotics, and pathological conditions associated with inflammation (67,68). The mechanism of LDL oxidation possesses the general characteristics of lipid peroxidation reactions and free-radical reactions (69).

Hypochlorous acid. HOCl is produced by the neutrophil-derived enzyme myeloperoxidase at sites of inflammation and when activated neutrophils infiltrate reoxygenated tissue (28). The enzyme oxidizes chloride ions, Cl−, in the presence of H2O2. A total of 5 × 105 activated human neutrophils in 1 mL produces 88 µM HOCl in 2 h at 22°C (70). HOCl is not a free radical, but it is a potent chlorinating and oxidizing agent. It has recently been suggested that the formation of cholesterol chlorohydrins could disrupt cell membranes and lead to cell lysis and death (71). On the basis of this observation, the cholesterol chlorohydrins have been suggested to be potential biomarkers for oxidative damage associated with neutrophil/methylene activation (71). HOCl can attack many other biological molecules. For example, the proteolytic inhibitor alpha-1-antiproteinase (α1AP) is the major inhibitor in human plasma of proteolytic enzymes, such as elastase. α1AP accounts for about 90% of the elastase-inhibitory capacity of the human serum (72). Thus, its inactivation by HOCl might greatly potentiate tissue damage because elastase is also released from activated neutrophils. HOCl attacks primary amines and sulfhydryl groups in proteins and chlorinates purine bases in DNA (73,74). Kozumbo et al. (75) have demonstrated that physiological levels of HOCl can react with substituted aryl amine (e.g., aniline, 1-naphthylamine, and 1-naphthol) to form long-lived products that bind DNA and are genotoxic to human cells.

In the context of food handling, HOCl is a major active constituent of chlorine-based bleaches that are often used to disinfect equipment with which foods will come into contact. Perhaps most significant is the observation that phenolic compounds can react effectively with HOCl, hence protecting susceptible targets against oxidation (76,77). This may have physiological significance, given the interest in the use of dietary natural antioxidants to manipulate disease states (78).

Superoxide radicals (O2−). O2− is an oxygen-centered radical with selective reactivity. This species is produced by a number of enzyme systems, by autooxidation reactions, and by nonenzymatic electron transfers that univalently reduce molecular oxygen. In aqueous solution, O2− can oxidize ascorbic acid. It can also reduce certain iron complexes such as cytochrome c and ferric-ethylenediaminetetraacetic acid (Fe3+-EDTA). Superoxide dismutase (SOD) accelerates the dismutation of O2−, converting it to H2O2 and O2. For an authoritative review, see References 10 and 79.

Hydrogen peroxide (H2O2). Like HOCl and O3, H2O2 is not a free radical. It can cross membranes and may slowly oxidize a number of compounds. H2O2 can be formed in vivo when O2− dismutates and also by many oxidase enzymes. H2O2 at low (micromolar) levels also seems to be poorly reactive. However, higher levels of H2O2 can attack several cellular energy-producing systems; for example, it inactivates the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase. H2O2 also forms OH− in the presence of transition metal ions, and O2 can facilitate this reaction.

Hydroxyl radicals. OH− is a highly reactive oxygen-centered radical with an estimated half-life in cells of only 10−9 s. Most studies on OH−, prior to the discovery of SOD, were done by radiation chemists. One feature of OH− is that it begets another radical, i.e., when it reacts with a molecule, the result is the formation of another radical species. The resulting species usually has lower reactivity than OH−. OH− attacks all proteins, DNA, PUFA in membranes, and almost any biological molecule it touches.

In the case of OH− generation by Fenton-type chemistry, the extent of OH− formation is largely determined by the availability and location of the metal ion catalyst. In an in vitro study, in which the technique of gas chromatography–mass spectrometry with selected ion monitoring (GC/MS/SIM) was used to compare the role of copper and iron ions in promoting damage to DNA by H2O2, added copper ions (80) were significantly more reactive in causing DNA damage in the presence of H2O2 than were equimolar iron ions. The availability of “free” iron and copper in vivo is controlled. Iron ions are absorbed from the gut and transported to iron-requiring cells by the protein transferrin. Iron specifically bound to transferrin does not participate in free-radical reactions. Excess iron is stored as ferritin and hemosiderin in an attempt to keep the iron pool as small as possible. Most or all of the plasma copper in humans is attached to the protein ceruloplasmin, which will not stimulate free-radical reactions under normal conditions (81,82). Hydroxyl radical generation can take place when the hemostasis is altered.
For example, copper and iron ions released into perfusates can cause ischemia/reperfusion injury (83). Ramos et al. (84), using the electron spin resonance (ESR) spin-trapping system, detected OH· as the α-hydroxyethyl spin-trapped adduct of 4-pyridyl 1-oxide N-tert-butyl nitronate, formed from phorbolester 12-myristate 13-acetate-stimulated human neutrophils and monocytes without the addition of supplemental iron. In systems that lacked myeloperoxidase, it is necessary to add iron to detect the OH· adduct. Thus, human neutrophils and monocytes can generate OH· through a myeloperoxidase-dependent mechanism (85), which could have microbicidal implications.

Tissue injury can itself cause ROS generation (e.g., by causing activation of phagocytes or releasing transition metal ions from damaged cells), which may (or may not, depending on the situation) contribute to a worsening of the injury. For example, the sequelae of traumatic brain injury and stroke may involve a postinjury stimulation of iron ion-dependent free-radical reactions. Parkinson’s disease is caused by death of cells in the substantia nigra. Lysis of dead cells could cause iron ion release. Thus, patients with Parkinson’s disease may be under oxidative stress, and free-radical reactions probably contribute to the degeneration of the substantia nigra (86).

PROTECTION AGAINST ROS-INDUCED DAMAGE

Some generation of ROS in vivo is unavoidable and may be deliberate; NO· is a typical example. The most important route for the formation of NO· is the oxidation of arginine by NOS of which there are two types; the constitutive calcium/calmodulin-dependent forms (cNOS), which produce low levels of NO·, and the inducible forms (iNOS). The iNOS, which have tightly bound calmodulin, are permanently active and are capable of generating high levels of NO· (37,38,42,43,87). The phagocytes (neutrophils, monocytes, macrophages, eosinophils) that defend against foreign organisms are also involved in this good and bad scenario. They generate O2−, H2O2, and (in the case of neutrophils) HOCl as one of their mechanisms for killing foreign organisms (26,27). This essential defense mechanism can go awry: several diseases (such as rheumatoid arthritis and inflammatory bowel disease) are accompanied by excessive phagocyte activation and resulting tissue damage, to which ROS contribute.

Human defenses against ROS-induced damage include the enzymes catalase and glutathione peroxidase (both of which remove H2O2, as well as SOD, which catalyzes the dismutation of O2− to form H2O2 and O2−). Glutathione peroxidase is generally thought to be more important than catalase as a H2O2-removing system in humans. Catalase is located in peroxisomes, whereas glutathione peroxidase is localized in the mitochondria and cytosol, a similar distribution to that of SOD. Interestingly, in mammalian (including human) tissues, SOD is mainly an intracellular enzyme. Only small amounts are present in extracellular fluids, such as plasma, cerebrospinal fluid or synovial fluid. In addition, some low-molecular-mass substances, such as uric acid, ascorbate (vitamin C), glutathione, tocopherol (vitamin E), ubiquinol, ergothioneine, hypotaurine, and lipoic acid, may act as antioxidants in the human body. Much has been written about the antioxidant status of the biological system. References 17, 19, 78, and 88–98 are illustrative.

The rates of free-radical generation probably increase in most diseases, although we still do not know how important they are in promoting tissue injury, mainly because of the limitations of the assays used to measure them. The development and validation of assays, indicated in Table 3 for humans, should allow us to rapidly evaluate the role of free radicals in disease pathology and establish a logical basis for the therapeutic use of antioxidants. Numerous antioxidant supplementation studies (17,18,99–117) for the primary prevention of chronic diseases have been undertaken. The principal endpoint has always been “incidence” of the respective disease,

| TABLE 3 |
| Measurement of Oxidative Damage in Humans |
| OXIDATIVE DNA DAMAGE |
| Gas chromatography–mass spectrometry–selected ion monitoring detection of oxidized base products |
| High-performance liquid chromatography-based assays for oxidized base products |
| Single gel electrophoresis assay (COMET ASSAY) |
| OXIDATIVE DAMAGE TO LIPIDS |
| Measurement of conjugated dienes |
| Measurement of isoprostanes |
| Measurement of hydroperoxides |
| Measurement of thiobarbituric acid-reactive materials by HPLC |
| ASSESSMENT OF THE LEVELS OF ANTIOXIDANT ENZYMES |
| Catalase, superoxide dismutase, and glutathione peroxidase |
| ASSESSMENT OF PROTEIN DAMAGE |
| Steady-state protein damage can be quantified in terms of the numbers of protein carbonyls and modified tyrosine residues. Total ongoing (repaired) protein damage can be indicated by the concentration of modified tyrosines and fluorescent bititrosines in urine. |
| ASSESSMENT OF LEVELS OF LOW MOLECULAR WEIGHT ANTIOXIDANTS AND VITAMINS |
| Uric acid/allantoin, glutathione, flavonoids, vitamins E and C, β-carotene |

*There are several indicators of the extent of oxidative damage in humans. Only the most common are included in this table.*
i.e., incidence of cancer or cardiovascular disease. In a departure from this, Duthie et al. (20) investigated the extent of oxidative DNA damage in Scottish men aged 50–59 years. Their result suggests that long-term antioxidant supplementation can decrease both endogenous and exogenous oxidative DNA damage in lymphocytes. I suggest that the application and validation of the biochemical markers in Table 3 should be built into future supplementation studies to evaluate the pharmacology of antioxidants (drug- or plant-derived antioxidants). It is necessary to balance this with the choice of population, formulation and dose of antioxidants being used, the expected outcome variables, and the pathologic end points.

MEASURING OXIDATIVE DAMAGE IN VIVO

The remainder of this article will focus on the technology (emerging and established) for assessing the products of oxidative damage to DNA, proteins, and lipids in context human diseases.

Measurement of oxidative DNA damage. Oxidative damage to DNA seems to occur continuously in vivo, in that low levels (presumably a “steady-state” balance between DNA damage and repair) have been detected in DNA isolated from human cells and tissues. The pattern of damage to the purine and pyrimidine bases bears the chemical fingerprint of OH- attack, suggesting that OH- formation occurs within the nucleus in vivo (117–123) (Scheme 2, DNA base products). However, this raises the question of how OH- could be produced in the nucleus. If OH- is attacking DNA, it must be produced close to the DNA because OH- is so reactive that it cannot diffuse from its site of formation. Background radiation may be one source, but radiation-generated OH- is formed over the whole cell and only a small fraction hits DNA (119). Other potential sources of OH- or OH- like species include the decomposition of ONOO-, the reaction of O2•− with HOCl, the attack of HOCl on DNA bases, and generation of chlorinated products. The greatest interest has been in reactions of transition-metal ions with H2O2 as a source of OH- (80, 120–122). The key question is whether “catalytic” transition-metal ions (e.g., iron and copper ions) are really in close proximity to DNA in vivo. Although iron and copper seem to be present in the nucleus (123,124), it remains to be established why and how they reach the DNA because these ions are normally carefully sequestered by the human body.
However, oxidative stress and cell death can liberate metal ions from their normal sequestration sites and might then bind to DNA, a powerful metal ion chelator. Extensive reviews on the chemistry and measurement of oxidative DNA damage may be found in References 120 and 125. Base products may be measured essentially as described in References 126–130.

There are two types of measurement of oxidative DNA damage. Steady-state damage can be measured when DNA is isolated from human cells and tissues and analyzed for base damage products: it presumably reflects the balance between damage and DNA repair. Hence, a rise in steady-state oxidative DNA damage could be due to increased damage and/or decreased repair. The measurement of baseline levels of oxidatively modified DNA bases, although important, does not necessarily provide information as to whether this damage is in active genes or quiescent DNA. It is important also to have an index of total DNA damage in the human body, i.e., the "input" side of the steady-state equation. The most common approach has been to assess the "output" side, i.e., trying to estimate the rate of repair of oxidized DNA.

Several DNA base damage products are excreted in human urine, including the nucleosides 8-hydroxy-deoxyguanosine (8-OHdG), 8-hydroxy-adenine, and 7-methyl-8-hydroxycytidine (131–133), but the one most exploited is 8-OHdG, usually measured by a method involving high-performance liquid chromatography (HPLC) with electrochemical detection. GC/MS has also been used to measure 8-OHdG in urine, and the limit of detection was 1.8 pmol, corresponding to a level of 8-OHdG in urine of 35 nM (134). The level of 8-OHdG in urine is presumably unaffected by the diet because nucleosides are not absorbed from the gut. The question of whether any 8-OHdG is metabolized to other products in humans has not been rigorously addressed. It is also possible that some or all of the 8-OHdG excreted in urine may arise not from DNA, but from deoxyGTP (dGTP) in the DNA precursor pool of nucleotides. An enzyme has been described that hydrolyzes dGTP-containing oxidized guanine to prevent its incorporation into DNA (135,136). The development of alternative urinary markers of total-body oxidative damage, to address these uncertainties and to validate measurements of guanine damage products in DNA by HPLC and GC/MS is the focus of current investigations (reviewed in Ref. 137).

**LIPIDS: LIPID PEROXIDATION AND THEIR MEASUREMENT**

Lipid peroxidation is important in vivo. It contributes to the development of cardiovascular diseases, such as preeclampsia and atherosclerosis, and the end-products of this process [particularly cytotoxic aldehydes, such as malondialdehyde (MDA) and 4-hydroxynonenal (HNE)] can cause damage to proteins and to DNA. Peroxidation causes impairment of biological membrane functioning, e.g., decreases fluidity, inactivates membrane-bound enzymes and receptors, and may change nonspecific calcium ion permeability (31,32). The more unsaturated a fatty acid side-chain, the greater its propensity to undergo lipid peroxidation. But do PUFA really peroxidize faster than saturated fatty acids in vivo? This question is particularly important in relation to proposals that increases in dietary polyunsaturation/saturated ratios are beneficial to health (reviews in 64,66,137). The ability to measure levels of isoprostanes and hydroxyeicosatetraenoic acids (HETE) represents an important development in attempts to measure clinically relevant oxidative lipid damage. The hydroperoxides HETE and isoprostanes are biologically active. HETE are chemotactic for neutrophils and facilitate calcium uptake and protein kinase C mobilization (138, 139). The 12-HETE are involved in adrenocorticotropin and parathyroid secretion, modulation of mitogenic processes, and lymphocyte function (140–142), while the 15-HETE may inhibit neutrophil migration across cytokine-activated endothelium (143). HETE can be measured by GC–MS, operated in the negative ion chemical ionization mode (144–146). Isoprostanes (Scheme 3) are a series of prostaglandin-like compounds that are formed during peroxidation of arachidonic acid, although probably similar products are formed from other PUFA. Because they are structurally similar to prostaglandin F2α, the compounds are collectively referred to as F2-isoprostanes. These compounds can be measured in plasma (35 ± 6 pg/mL) and urine (1600 ± 600 pg/mg creatinine) of healthy volunteers, indicative of ongoing lipid peroxidation even in healthy human subjects. Most of the plasma isoprostanes is esterified to phospholipids, but some are “free.” One of the isoprostanes, 8-iso PGF2α, is a powerful renal vasoconstrictor and decreases kidney blood flow and glomerular filtration rate by almost half at low nanomolar concentrations. It has been suggested that elevated circulating concentrations of F2-isoprostanes may contribute to the pathology of hepatorenal syndrome, an almost uniformly fatal disorder characterized by the development of kidney failure in patients with severe liver disease. Urinary excretion of isoprostanes is elevated in patients with scleroderma and in smokers (extensive reviews may be found in Refs. 67,68,144,147,148). Isoprostanes and their metabolites can be measured in human urine, and this may prove to be a valuable assay of whole-body lipid peroxidation if a confounding effect of diet can be ruled out. The mechanism of formation of the isoprostanes is shown in Scheme 3, including the pathways (without the sterochemical orientation for clarity) that lead to the formation of four regioisomers (I–IV) of isoprostanes. The endoperoxides can undergo reduction to produce F2-isoprostanes or rearrangements to form the E2-isoprostanes, D2-isoprostanes, and/or isothromboxanes (68).

**OXIDATIVE DAMAGE TO PROTEINS AND THEIR MEASUREMENT**

Oxidative damage to proteins in vivo may affect the function of receptors, enzymes, transport proteins, etc. and perhaps generate new antigens that provoke immune responses. Products of oxidative protein damage can contribute to secondary damage to other biomolecules, e.g., inactivation of DNA repair enzymes and loss of fidelity of DNA polymerases in
The chemical reactions that result from attack of ROS upon proteins are complex (152). Free-radical attack upon proteins generates radicals from amino acid residues, and electrons can be transferred between different amino acids (Scheme 4, products of oxidative protein damage) (137,149). The levels of any one (or, preferably, of more than one) of these products in proteins could in principle be used to assess the balance between oxidative protein damage and the repair of (or, more likely, hydrolytic removal of) damaged proteins. The only product exploited to date has been hydroxylated phenylalanine. For example, levels of ortho-tyrosine and di-tyrosine in human lens proteins have been reported in relation to age (153). RNS in Scheme 4 refers to reactive nitrogen species, such as NO and peroxynitrite.

The carbonyl assay (154), a general assay of oxidative pro-
tein damage, to assess steady-state protein damage in human tissues and body fluids is based on the fact that several ROS can attack histidine, arginine, lysine, and proline residues in proteins to produce carbonyl functions that can be measured after reactions with 2,4-dinitrophenyldiazine (DNPH) (149,155–158). Immunochemical methods involving anti-DNPH antibodies have also been described (159,160). Nevertheless, the reader is referred to the seminal discussions of the mechanisms and the molecular biology of oxidative damage to proteins (in Refs. 161–163).

ROS are formed in the human body. When endogenous antioxidant defenses are inadequate for the purpose of scavenging the ROS completely, ongoing oxidative damage to DNA, lipids, proteins and other molecules can be demonstrated. Although ROS have been implicated in pathology of several human diseases, it is important to appreciate that ROS may not be the primary cause of these diseases. Although diet-derived and drug-derived antioxidants may be particularly important in protecting against a number of human diseases (see Table 2), the physiological relevance of these effects is uncertain. The effects of dietary antioxidants and/or antioxidant supplements in vivo are best studied using a combination of validated methods (see Table 3) for measuring oxidative damage and where a particular disease is being investigated, the respective disease end point (164). This should now become part of the strategy for future antioxidant supplementation and intervention studies of any kind.

ACKNOWLEDGMENTS

I thank Nestec SA Switzerland, the UK Ministry of Agriculture, Fisheries and Food, and the World Cancer Research Fund for research support.

REFERENCES

1. Gomberg, M., An Incidence of Trivalent Carbon Trimethylphenyl, J. Am. Chem. Soc. 22:757–771 (1900).
2. Hey, D.H., and W.A. Waters, Some Organic Reactions Involving the Occurrence of Free Radicals in Solution, Chem. Rev. 21:169–208 (1937).
3. Cadogan, J.I.G., Principles of Free Radical Chemistry, The Chemical Society, London, 1973.
4. Weiss, J., Investigations of the Radical HO₂ in Solution, Trans. Faraday Soc. 31:668–681 (1935).
5. Perkins, M.J., Radical Chemistry, Ellis Horwood, London, 1996.
6. Moad, G., and D.H. Solomon, The Chemistry of Free Radical Polymerization, Pergamon, Oxford, 1995.
7. Waters, W.A., A Chemical Interpretation of the Mechanism of Oxidation by Dehydrogenase Enzymes, Trans. Faraday Soc. 39:140–151 (1943).
8. Gerschman, R., D.L. Gilbert, S.W. Nye, P. Dwyer, and W.O. Fenn, Oxygen Poisoning and X-Irradiation: A Mechanism in Common, Science 119:623–626 (1954).
9. McCord, J.M., and I. Fridovich, Superoxide Dismutase. An Enzymatic Function for Erythrocytoprein (Hemocuprin), J. Biol. Chem. 224:6049–6055 (1969).
10. Michelson, A.M., J.M. McCord, and I. Fridovich, Superoxide and Superoxide Dismutases, Academic Press, London, 1977.
11. Aruoma, O.I., Free Radicals and Foods, Chem. Br. 29:210–214 (1993).
12. Porter, W.L., Paradoxical Behaviour of Antioxidants in Food and Biological Systems, Toxicol. Ind. Health 9:93–122 (1993).
13. Hudson, B.J.F., Food Antioxidant, Elsevier Applied Science London.
14. Frankel, E.N., Lipid Oxidation, Prog. Lipid Res. 19:1–22 (1980).
15. Papas, A.M., Oil-Soluble Antioxidants in Foods, Toxicol. Ind. Health 9:123–149 (1993).
16. Lölliger, R., The Use of Antioxidants in Food, in Free Radicals and Food Additives, edited by O.I. Aruoma and B. Halliwell, Taylor & Francis, London, 1991, pp. 121–150.
17. Diplock, A.T., Antioxidant Nutrients and Disease Prevention: An Overview, J. Clin. Nutr. 53:1895–1938.
18. Block, G., B. Pattersen, and A. Subar, Fruit, Vegetables and Cancer Prevention: A Review of the Epidemiological Evidence. Nutr. Cancer 18:1–29 (1992).
19. Aruoma, O.I., Characterization of Drugs as Antioxidant Prophylactics, Free Radical Biol. Med. 20:675–705 (1996).
20. Duthie, S.J., A. Ma, M.A. Ross, and A.R. Collins, Antioxidant Supplementation Decreases Oxidative DNA Damage in Human Lymphocytes, Cancer Res. 56:1291–1295 (1996).
21. Pezzuto, J.M., Plant-Derived Anticancer Agents, Biochem. Pharmacol. 53:121–133 (1997).
22. Pryor, W.A., Free Radical Biology: Xenobiotics, Cancer, and Aging, Ann. N.Y. Acad. Sci. 393:1–22 (1982).
23. Southorn, P.A., and G. Powis, Free Radicals in Medicine II, Involvement in Human Disease, Mayo Clin. Proc. 63:390–408 (1988).
24. Halliwell, B., and J.M.C. Gutteridge, Free Radicals in Biology and Medicine, Clarendon Press Oxford, 1989.
25. Aruoma, O.I., Free Radicals in Tropical Diseases, Harwood Academic Publishers, London, 1991.
26. Babior, B.M., Oxidants from Phagocytes: Agents of Defense and Destruction, Blood 64:959–966 (1984).
27. Klebanoff, S.J., Oxygen Metabolism and the Toxic Properties of Phagocytes, Ann. Intern. Med. 93:480–489 (1980).
28. Weiss, S.J., Tissue Destruction by Neutrophils, New Engl. J. Med. 320:365–376 (1989).
29. Del-Maestro, R.F., An Approach to Free Radicals in Medicine and Biology, Acta Physiol. Scand. suppl. 492:153–168 (1980).
30. For a collection of review articles, see Oxygen Radicals and Lung Injury, Environ. Health Perspect. 102 (suppl 10) 5–213 (1994).
31. Orrenius, S., D.J. McConkey, G. Bellomo, and P. Nicotera, Role of Ca²⁺ in Toxic Cell Killing, Trends Pharmacol. Sci. 10:281–285 (1989).
32. Bast, A., Oxidative Stress and Calcium Homeostasis, in Free Radicals and Free Radicals, edited by B. Halliwell and O.I. Aruoma, Ellis Horwood, London, 1993, pp. 95–108.
33. Stokinger, H.E., Ozone Toxicology, Arch. Environ. Health 10:719–731 (1965).
34. Mustafa, M.G., Biochemical Basis of Ozone Toxicity, Free Radical Biol. Med. 9:245–265 (1990).
35. Pryor, W.A., Mechanism of Radical Formation from Reactions of Ozone with Target Molecules in the Lung, Ibid. 17:451–465 (1994).
36. Kanofsky, J.R., and P. Sima, Singlet Oxygen Production from the Reactions of Ozone with Biological Molecules, J. Biol. Chem. 266:9039–9042 (1991).
37. Palmer, R.M.J., D.S. Ashton, and S. Moncada, Vascular Endothelium Cell Synthesize Nitric Oxide from L-Arginine, Nature 333:664–666 (1988).
38. Ignarro, L.J., G.M. Buga, K.S. Wood, R.E. Byrns, and G. Chandhuri, Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein Is Nitric Oxide, Proc. Natl. Acad. Sci. USA 84:9265–9269 (1987).
39. Sneddon, J.W., and J.R. Vane, Endothelium-Derived Relaxing Factor Reduces Platelet Adhesion to Bovine Endothelium
Cells, *Ibid.* 85:1341–1344 (1988).
40. Gaston, B., J.M. Drazen, J. Lescalzo, and J.S. Stamler, *The Biology of Nitrogen Oxide in the Airways, Am. J. Respir. Crit. Care Med.* 149:538–551 (1994).
41. Anggärd, E., Nitric Oxide: Mediator, Murderer and Medicine, *Lancet* 343:1199–1206 (1994).
42. Rubbo, H., V. Darley-Usmar, and B.A. Freeman, Nitric Oxide Regulation of Tissue Free Radical Injury, *Chem. Res. Toxicol.* 9:809–820 (1996).
43. Lancaster, J., ed., *The Biological Chemistry of Nitric Oxide*, Academic Press, New York, 1995.
44. Sessa, W.C., K. Pritchard, N. Seyedi, J. Wang, and T.H. Shaw, *Nitric Oxide, Leukocyte Activation and Antioxidant Depletion*, pp. 39–66.
45. Spencer, J.P.E., A. Jenner, O.I. Aruoma, C.E. Cross, and B. Tannenbaum, Nitric Oxide Induces Oxidative Damage in Addition to Deamination in Macrophage DNA, *Chem. Res. Toxicol.* 8:473–477 (1995).
46. Douki, H., and J. Cadet, Peroxynitrite Mediated Oxidation of Purine Bases of Nucleosides and Isolated DNA, *Free Rad. Res.* 24:369–380 (1996).
47. Updu, R.M., R. Cueto, G.L. Squidrito, M.G. Salgo, and W.A. Pryor, Reactions of Peroxynitrite with 2-Deoxyguanosine, 7,8-dihydro-8-oxo-2’-deoxyguanosine, and Calf-thymus DNA, *Free Radical Biol. Med.* 21:407–411 (1996).
48. Merchant, K., H. Chen, T.C. Gonzalez, L.K. Keefer, and B.R. Shaw, Deamination of Single-Stranded DNA Cytosine Residues in Aerobic Nitric Oxide Solution at Micromol Total NO Exposures, *Chem. Res. Toxicol.* 9:891–896 (1996).
49. Douki, T., J. Cadet, and B.N. Ames, An Adduct Between Peroxynitrite and 2’-Deoxyguanosine: 4,5-Dihydro-5-hydroxy-4-(nitrosooxy)-2’-deoxyguanosine, *Ibid.* 9:3–7 (1996).
50. Yermilov, V., J. Rubio, and H. Ohshima, Formation of 8-Nitroguanine in DNA Treated with Peroxynitrite in vitro and Its Rapid Removal from DNA by Depurination, *FEBS Lett.* 376:207–210 (1995).
51. Spencer, J.P.E., A. Jenner, O.I. Aruoma, C.E. Cross, and B. Halliwell, Base Modification and Strand Breakage in Isolated Calf Thymus DNA and in DNA from Human Skin Epidermal Keratinocytes Exposed to Peroxynitrite or 3-Morpholinosydnonimine, *Chem. Res. Toxicol.* 9:1152–1158 (1996).
52. Salgo, M.G., K. Stone, G.L. Squidrito, J.R. Battista, and W.A. Pryor, Peroxynitrite Causes DNA Nicks in Plasmid pBR322, *Biochem. Biophys. Res. Commun.* 210:1026–1030 (1995).
53. Huie, R.E., and S. Padmanja, The Reaction of NO with Superoxide, *Free Radical Res. Commun.* 18:195–199 (1993).
54. van der Vliet, A., D. Smith, C.A. O’Neill, H. Kaur, V. Darley-Usmar, C.E. Cross, and B. Halliwell, Interactions of Peroxynitrite with Human Plasma and Its Constituents: Oxidative Damage and Antioxidant Depletion, *Biochem. J.* 303:295–301 (1994).
55. Gatti, R.M., O. Augusto, J.K. Kwee, and S. Giorgio, Leishmanicidal Activity of Peroxynitrite, *Redox Rep.* 1:261–265 (1995).
56. Watts, B.P., M. Barnard, and J.F. Turrens, Peroxynitrite-Dependent Chemoluminescence of Amino Acids, Proteins and Intact Cells, *Arch. Biochem. Biophys.* 317:324–330 (1995).
57. Zhu, L., C. Gunn, and J.S. Beckman, Bactericidal Activity of Peroxynitrite, *Ibid.* 298:452–457 (1992).
58. Rudi, R., J.S. Beckman, K.M. Bush, and B.A. Freeman, Peroxynitrite Oxidation of Sulphydryls. The Cytotoxic Potential of Superoxide and Nitric Oxide, *J. Biol. Chem.* 266:4244–4250 (1991).
59. Tarpey, M.M., J.S. Beckman, H. Ischiropoulos, J.Z. Gore, and T.A. Brock, Peroxynitrite Stimulates Vascular Smooth Muscle Cell Cyclic GMP Synthesis, *FEBS Lett.* 364:314–318 (1995).
60. Kalyanaraman, B., V. Darley-Usmar, A. Struck, N. Hogg, and S. Parthasarathy, Role of Apolipoprotein-Derived Radical and α-Tocopherol Radical in Peroxidase-Dependent Oxidation of Low Density Lipoprotein, *J. Lipid Res.* 36:1037–1045 (1995).
61. Pryor, W.A., and G.L. Squidrito, The Chemistry of Peroxynitrite: A Product from the Reaction of Nitric Oxide with Superoxide, *Lung Cell. Mol. Physiol.* 12:1699–1722 (1995).
62. Graham, A., N. Hogg, B. Kalyanaraman, V. O’Leary, V. Darley-Usmar, and S. Moncada, Peroxynitrite Modification of Low-Density Lipoprotein Leads to Recognition by the Macrophage Scavenger Receptor, *FEBS Lett.* 330:181–185 (1993).
63. Ischiropoulos, H., and A.B. Al-Mehdi, Peroxynitrite Mediated Oxidative Protein Modifications, *Ibid.* 364:279–282 (1995).
64. Esterbauer, H., J. Gebicki, H. Puhl, and G. Juergens, The Role of Lipid Peroxidation and Antioxidants on Oxidative Modification of LDL, *Free Radical Biol. Med.* 13:341–390 (1992).
65. Cerrutti, P.A., Pro-oxidant States and Tumor Activation, *Science* 227:375–381 (1985).
66. Cheeseman, K.H., Lipid Peroxidation and Cancer, in *DNA and Free Radicals*, edited by B. Halliwell and O.I. Aruoma, pp. 109–144, Ellis Horwood, London, 1993.
67. Morrow, J.D., K.E. Hill, R.F. Burk, T.M. Mannour, K.F. Badr, and L.J. Roberts, A Series of Prostaglandin F2α Like Compounds Are Produced in vivo by Humans by a Non-cyclooxygenase, Free Radical Catalyzed Mechanism, *Proc. Natl. Acad. Sci. USA* 87:9383–9387 (1990).
68. Morrow, J.D., and L.J. Roberts, The Isoprostanes: Current Knowledge and Directions for Future Research, *Biochem. Pharmacol.* 51:1–9 (1996).
69. Esterbauer, H., The Chemistry of Oxidation of Lipoproteins, in *Oxidative Stress, Lipoproteins and Cardiovascular Dysfunction*, edited by C. Rice-Evans and K.R. Bruckdorfer, Portland Press, London, 1995, pp. 55–79.
70. Kalyanaraman, B., and P.G. Sohle, Generation of Free Radical Intermediates from Foreign Compounds by Neutrophil-Derived Oxidants, *J. Clin. Invest.* 75:1618–1622 (1985).
71. Carr, A.C., J.J.M. van den Berg, and C.C. Winterbourn, Chlorination of Cholesterol in Cell Membranes by Hypochlorous Acid, *Arch. Biochem. Biophys.* 332:63–69 (1996).
72. Travis, J., and G.S. Salvesen, Human Plasma Proteinase Inhibitors, *Annu. Rev. Biochem.* 52:655–709 (1983).
73. Dennis, W.H., V.P. Oliveieri, and C.W. Kruse, The Reaction of Nucleotides with Aqueous Hypochlorous Acid, *Water Res.* 13:357–362 (1979).
74. Gould, J.P., and T.R. Hay, The Nature of the Reactions Between Chlorine and Purine and Pyrimidine Bases: Products and Kinetics, *Wat. Res. Tech.* 14:629–640 (1982).
75. Kozumho, W.J., S. Agarwal, and H.S. Koren, Breakage and Binding of DNA by Reaction Products of Hypochlorous Acid with Aniline, 1-Naphthylamine or 1-Naphthol, *Toxicol. Appl. Pharmacol.* 115:107–115 (1992).
76. Aruoma, O.I., B. Halliwell, R. Aeschbach, and J. Löüger, Antioxidant and Pro-oxidant Properties of Active Rosemary Constituents: Carnosol and Carnosic Acid, *Xenobiotica* 22:257–268 (1992).
77. Aruoma, O.I., A. Murcia, J. Butler, and B. Halliwell, Evaluation of the Antioxidant Actions of Gallic Acid and Its Derivatives, *J. Food Chem.* 41:1880–1885 (1993).
78. Aruoma, O.I., Nutrition and Health Aspects of Free Radicals and Antioxidants, *Food Chem. Toxicol.* 32:671–683 (1994).
79. Fridovich, I., Superoxide Dismutases, An Adaptation to the Paramagnetic Gas, *J. Biol. Chem.* 264:7761–7764 (1989).
80. Aruoma, O.I., B. Halliwell, E. Gajeski, and M. Dizdaroglu, Copper-Ion Dependent Damage to the Bases in DNA in the Presence of Hydrogen Peroxide, *Biochem. J.* 273:601–604.
81. Aruoma, O.I., and B. Halliwell, Superoxide-Dependent and Ascorbate-Dependent Formation of Hydroxyl Radicals from Hydrogen Peroxide in the Presence of Iron: Are Lactoferrin and Transferrin Promoters of Hydroxyl Radical Generation, *Ibid.* 241:273–278 (1987).

82. Halliwell, B., and J.M.C. Gutteridge, Role of Free Radicals and Catalytic Metal Ions in Human Disease: An Overview, *Methods Enzymol.* 186:1–85 (1990).

83. Chevion, M., Y. Liang, R. Har-El, E. Berenshtein, G. Uretzky, and N. Kitrossky, Copper and Iron Are Mobilized Following Myocardial Ischemia: Possible Productive Criteria for Tissue Injury, *Proc. Natl. Acad. Sci. USA* 90:1102–1106 (1993).

84. Ramos, C.L., S. Pou, B.E. Britigan, M.S. Cohen, and G.M. Rosen, Spin Trapping Evidence for Myeloperoxidase-Dependent Hydroxyl Radical Formation by Human Neutrophils and Monocytes, *J. Biol. Chem.* 267:8307–8312 (1992).

85. O.I. ARUOMA

86. Olanow, C.W., P. Jenner, and M. Youdim, Antioxidants and Neuroprotection in Parkinson's Disease, *Academic Press*, London, 1996.

87. Moncada, S., and A. Higgs, The l-Arginine-Nitric Oxide Pathway, *New Engl. J. Med.* 329:2002–2012 (1993).

88. Ames, B.N., M.K. Shigenaga, and T.M. Hagen, Oxidants, Antioxidants, and the Degenerative Disease of Aging, *Proc. Natl. Acad. Sci. USA* 90:7915–7922 (1993).

89. Ganguly, P.K., Antioxidant Therapy in Congestive Heart Failure: Is There Any Advantage? *J. Intern. Med.* 229:205–208 (1991).

90. Frei, B. (ed.), *Natural Antioxidants in Human Health and Disease*, Academic Press, New York, 1994.

91. McCord, J.M., Human Disease, Free Radicals and the Oxidant/Antioxidant Balance, *Clin. Biochem.* 26:351–357 (1993).

92. Clemens, M.R., Antioxidant Therapy in Haematological Disorders, *Adv. Exp. Biol. Med.* 264:423–433 (1990).

93. Haumann, B.F., Antioxidants: Health Implications, *INFORM* 5:242–252 (1994).

94. Ong, A.S.H., and L. Packer (eds.), *Lipid-Soluble Antioxidants: Biochemistry and Clinical Applications*, Birkhauser, Basel, 1992.

95. Gutteridge, J.M.C., and B. Halliwell, *Antioxidants in Nutrition, Health and Disease*, Oxford University Press, Oxford, 1995.

96. Kumpulainen, J.T., and J.T. Salonen (eds.), *Natural Antioxidants and Food Quality in Atherosclerosis and Cancer Prevention*, Royal Society of Chemistry, London, 1996.

97. Halliwell, B., Antioxidants in Human Health and Disease, *Annu. Rev. Nutr.* 16:33–50 (1996).

98. Sies, H., *Antioxidants in Disease Mechanisms and Therapy*, Academic Press, London, Vol. 38, Advances in Pharmacology Series, 1996.

99. Stumper, M.J., C.H. Hennekens, J.E. Manson, G.A. Colditz, B. Rosner, and W.C. Willett, Vitamin E Consumption and the Associated Risk of Coronary Disease in Women, *New Engl. J. Med.* 328:1444–1449 (1993).

100. Knekt, P., A. Reunanen, R. Järvinen, R. Seppänen, M. Heliövaara, and A. Aromaa, Antioxidant Vitamin Intake and Coronary Mortality in a Longitudinal Population Study, *Am. J. Epidemiol.* 139:1180–1189 (1994).

101. Hertog, M.O.L., E.J.M. Feskens, P.C. Hollman, M.B. Katan, and D. Kromhout, Dietary Antioxidant Flavonoids and Risk of Coronary Heart Disease: The Zutphen Elderly Study, *Lancet* 342:1007–1011 (1993).

102. Gey, K.F., Long Term Adequacy of All Major Antioxidants, Presumably in Synergy with Other Vegetable-Derived Nutrients May Help to Prevent Early Stages of Cardiovascular Disease and Cancer Respectively, *Int. J. Vitamin Nutr. Res.* 65:65–69 (1995).

103. Manson, J.E., M.J. Stamper, W.C. Willett, G.A. Colditz, P.E. Speizer, and C.H. Hennekens, Consumption of Antioxidant Vitamins and Incidence of Stroke in Women, *Am. J. Epidemiol.* 138:603 (1993).

104. Gridley, G., J.K. McLaughlin, G. Block, W.J. Blot, M. Gluch, and J.F. Fraumeni, Vitamin Supplement Use and Reduced Risk of Oral and Pharyngeal Cancer, *Ibid.* 135:1083–1092 (1992).

105. Hankinson, S.E., J.J. Stamper, J.M. Seddon, B.A. Rosner, F.E. Speizer, and W.C. Willett, Nutrient Intake and Cataract Extraction in Women: A Prospective Study, *Brit. Med. J.* 305:335–339 (1992).

106. Gey, K.F., H.B. Stähelin, and M. Eichholzer, Poor Plasma Status of Carotene and Vitamin C Is Associated with Higher Mortality from Ischemic Heart Disease and Stroke: Basel Prospective Study, *Clin. Invest.* 73:3–6 (1993).

107. Jialal, I., and S.M. Grundy, Effect of Dietary Supplementation with Alpha-Tocopherol on the Oxidative Modification of Low Density Lipoprotein, *J. Lipid Res.* 33:899–906 (1992).

108. Blot, W.J., J.-Y. Li, P.R. Taylor, W. Guo, S. Dawsey, G.-Q. Wang, C.S. Yang, S.-F. Zheng, M. Gail, G.-Y. Li, Y. Yu, B.-Q. Liu, J. Tangrea, Y.-H. Sun, F. Liu, J.F. Fraumeni, Y.-H. Zhang, and B. Li, Nutrition Intervention Trials in Linxian, China, Supplementation with Specific Vitamin/Mineral Combinations, Cancer Incidence and Disease Specific Mortality in the General Population, *J. Natl. Cancer Inst.* 85:1483–1492 (1993).

109. West, S., S. Vitale, J. Hallfrisch, B. Munoz, D. Muller, S. Bressler, and N.M. Bressler, Are Antioxidants or Supplements Protective for Age Related Macular Degeneration, *Arch. Ophthalmol.* 112:222–227 (1994).

110. Greenberg, E.R., J.A. Baron, T.D. Tostesen, D.H. Freeman, G.J. Beck, J.H. Bond, T.A. Colacchio, J.A. Collier, H.D. Frankl, R.W. Haile, J.S. Mandel, D.W. Nierenberg, R. Rothschild, D.C. Snozer, N.M. Stevens, R.W. Summers, and R.U. van Stolk, A Clinical Trial of Antioxidant Vitamins to Prevent Cataract, *Arch. Ophthalmol.* 112:222–227 (1994).

111. Heinonen, O.P., and D. Albanes, The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group), *Ibid.* 330:1029–1034 (1994).

112. Henekens, C.H., J.E. Buring, J.E. Manson, B. Stamper, B. Rosner, N.R. Cook, C. Belanger, F. Lamotte, J.M. Gaziano, A.M. Fradkin, R.W. Haile, J.S. Mandel, D.W. Nierenberg, R. Rothchild, D.C. Snozer, N.M. Stevens, R.W. Summers, and R.U. van Stolk, A Clinical Trial of Antioxidant Vitamins to Prevent Cataract, *Arch. Ophthalmol.* 112:222–227 (1994).

113. Gillman, M.W., L.A. Cupples, D. Gagnon, B.M. Posner, R.C. Ellison, W.P. Castelli, and P.A. Wolf, Protective Effect of Fruits and Vegetables on Development of Stroke in Men, *J. Am. Med. Assoc.* 273:1113–1117 (1995).

114. Stephens, N.G., A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseeman, M.J. Mitchinson, and M.J. Brown, Randomised Controlled Trial of Vitamin E in Patients with Coronary Diseases: Cambridge Heart Antioxidant Study (CHAOS), *Lancet* 347:781–786 (1996).

115. Gey, K.F., Ten Year Retrospective on the Antioxidant Hypothesis of Atherosclerosis: Threshold Plasma Levels of Antioxidant Micronutrients Related to Minimum Cardiovascular Risk, *J. Nutr. Biochem.* 6:206–236 (1996).

116. Omenn, G.S., G.E. Goodman, M.D. Thornquist, J. Balmes, M.R. Cullen, A. Glass, J.P. Keogh, F.L. Meyskens, B. Valanis, J.H. Williams, S. Barnhart and S. Hammer, Effect of a Combination of β-Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease, *New Engl. J. Med.* 334:1150–1155 (1996).

117. Spencer, J.P.E., A. Jenner, O.I. Aruoma, C.E. Cross, R. Wu, and B. Halliwell, Oxidative DNA Damage in Human Respiratory Tract Epithelial Cells. Time Course in Relation to DNA Strand
Breakage, Biochem. Biophys. Res. Commun. 224:17–22 (1996).

118. Jaruga, P., and M. Dizdaroglu, Repair of Products of Oxidative DNA Base Damage in Human Cells, Nucleic Acids Res. 24:1389–1394 (1996).

119. Nackerdien, Z., R. Olinski, and M. Dizdaroglu, DNA Base Damage in Chromatin of γ-Irradiated Cultured Human Cells, Free Radical Res. Commun. 16:259–273 (1992).

120. Breen, A.P., and J.A. Murphy, Reactions of Oxy radicals with DNA, Free Radical Biol. Med. 18:1033–1077 (1995).

121. Brynes, R.W., Evidence for Involvement of Multiple Iron Species in DNA Single-Strand Scission by H_2O_2 in HL-60 Cells, Ibid. 20:399–406 (1996).

122. Klein, C.B., K. Frenkel, and M. Costa, The Role of Oxidative Processes in Metal Carcinogenesis, Chem. Res. Toxicol. 4:592–604 (1991).

123. Dizdaroglu, M., Chemical Determination of Free Radical Involvement in DNA, Free Radical Biol. Med. 10:225–242 (1991).

124. Spencer, J.P.E., A. Jenner, O.I. Aruoma, P.J. Evans, H. Kaur, D.T. Drexler, P. Jenner, A.J. Lees, D.C. Marsden, and B. Halliwell, Intense Oxidative DNA Damage Promoted by L-DOPA and Its Metabolites. Implications for Neurodegenerative Disease, FEBs Lett. 353:246–250 (1994).

125. Collins, A.R., S.J. Duthie, and V.L. Dobson, Direct Enzymic Detection of Endogenous Oxidative Base Damage in Human Lymphocyte DNA, Carcinogenesis 14:1733–1735 (1993).

126. Herbert, K.E., M.D. Evans, M.T.V. Finnegan, S. Farooq, N. Mistry, I.D. Podmore, P. Farmer, and J. Lunec, A Novel HPLC Procedure for the Analysis of 8-Oxoguanine in DNA, Free Radical Biol. Med. 20:467–473 (1996).

127. Shigenaga, M.K., C.J. Gimeno, and B.N. Ames, Urinary 8-Hydroxy 2′Deoxyguanosine as a Biological Marker of in vivo Oxidative DNA Damage, Proc. Natl. Acad. Sci. USA 86: 9697–9701 (1989).

128. Loft, S., A. Fischer-Nielsen, and I.B. Jeding, 8-Hydroxydeoxyguanosine as a Urinary Marker of Oxidative DNA Damage, J. Toxicol. Environ. Health 40:391–404 (1993).

129. Stillwell, W.G., H.X. Xu, J.A. Adkins, J.S. Wishnok, and S.R. Tannenbaum, Analysis of Methylated and Oxidized Purines in Urine by Capillary Gas Chromatography–Mass Spectrometry, Chem. Res. Tox. 2:94–99 (1989).

130. Teixeira, A.J.R., J.H. Gommer-ampt, G. van de Weerken, J.G. Westra, J.F.C. Stavenveter, and A.P.J.M. de Jong, Method for the Analysis of Oxidized Nucleosides by Gas Chromatography/Mass Spectrometry, Anal. Biochem. 214:474–483 (1994).

131. Sakumi, K., M. Furuchi, T. Tsuzuki, T. Kakuma, S. Kawabata, H. Maki, and M. Sekiguchi, Cloning and Expression of cDNA for a Human Enzyme That Hydrolyzes 8-Oxo-dGTP, a Mutagenic Substrate for DNA Synthesis, J. Biol. Chem. 268:23524–23530 (1993).

132. Mo, J.Y., H. Maki, and M. Sekiguchi, Hydrolytic Elimination of a Mutagenic Nucleotide, 8-OxodGTP, by Human 18-Kilodalton Protein; Sanitization of Nucleotide Pool, Proc. Natl. Acad. Sci. USA 89:11021–11025 (1992).

133. Halliwell, B., and O.I. Aruoma, Free Radicals and Antioxidants: The Need for in vivo Markers of Oxidative Stress, in Antioxidant Methodology: In Vivo and In Vitro Concepts, edited by O.I. Aruoma and S. Cuppert, AOCS Press, Champaign, 1997.

134. Goetzl, E.J., J.M. Woods, and R.R. Gorman, Stimulation of Human Eosinophil and Neutrophil Polymorphonuclear Leukocyte Chemotaxis and Random Migration by 12-1-Hydroxy-5,8,10,14-eicosatetraenoic Acid, J. Clin. Invest. 59:179–183 (1977).

135. O’Flaherty, J.T., and J. Nishihira, 5-Hydroxyecosatetraenoic Promotes Ca_2+_ and Protein Kinase Mobilisation in Neutrophils, Biochem. Biophys. Res. Commun. 148:575–581 (1987).

136. Won, J.G., and D.N. Orth, The Role of Lipoxigenase Metabolite of Arachidonic Acid in the Regulation of Adrenocorticotropin Secretion by Per fused Rat Anterior Pituitary Cells, Endocrinology 135:1496–1503 (1994).

137. Halliwell, B., and O.I. Aruoma, Free Radicals and Antioxidants: The Need for in vivo Markers of Oxidative Stress, in Antioxidant Methodology: In Vivo and In Vitro Concepts, edited by O.I. Aruoma and S. Cuppert, AOCS Press, Champaign, 1997.

138. Joulian, C., N. Meskini, G. Anker, M. Lagarde, and A.F. Pri gent, Esterification of 12(S)-Hydroxy-5,8,10,14-eicosatetraenoic Acid into the Phospholipids of Human Peripheral Blood Mononuclear Cells: Inhibition of the Proliferative Response, J. Cell. Physiol. 164:154–163 (1995).

139. Bourdeau, A., M. Mourahir, J.C. Souberbielle, P. Bonnet, P. Herviaux, C. Sachs, and M. Lieberherr, Effects of Lipoxigenase Products of Arachidonate Metabolism on Parathyroid Hormone Secretion, Endocrinology 135:1109–1112 (1994).

140. Takata, S., A. Papayianni, M. Matsubara, W.R. Brady, 15-Hydroxyecosatetraenoic Acid Inhibits Neutrophil Migration Across Cytokine-Activated Endothelium, Am. J. Pathol. 145:541–549 (1994).

141. Noupoooz-Zadeh, J., N.K. Gopaul, S. Barrow, A.I. Mallet, and E.E. Anggärd, Analysis of F_2-isoprostanes as Indicators of Non-enzymatic Lipid Peroxidation in vivo by Gas Chromatography–Mass Spectrometry: Development of a Solid-Phase Extraction Procedure, J. Chromatogr. B667:199–208 (1995).

142. Guido, G.M., R. McKenna, and W.R. Matthews, Quantitation of Hydroprooxy-Eicosatetraenoic Acids and Hydroxy-Eicosatetraenoic Acids as Indicators of Lipid Peroxidation Using Gas Chromatography–Mass Spectrometry, Anal. Biochem. 209:123–129 (1993).

143. Morrow, J.D., M.A. Awad, T. Kato, K. Takahashi, K.F. Baid, L.J. Roberts, and R.F. Burk, Formation of Novel Non-cyclooxygenase Derived Prostanoids (F_3-isoprostanes) in Carbon-bondetrachloride Hepatotoxicity: An Animal Model of Lipid Peroxidation, J. Clin. Invest. 90:2502–2507 (1992).

144. Bachi, A., E. Zuccato, M. Beraldi, R. Fanelli, and C. Chiabrando, Measurement of Urinary 8-Epi–prostaglandin F_2 alpha, A Novel Index of Lipid Peroxidation in vivo, by Immunoaffinity Extraction/Gas Chromatography–Mass Spectrometry. Basal Levels in Smokers and Nonsmokers, Free Radical Biol. Med. 20:619–624 (1996).

145. Morrow, J.D., T.A. Minton, C.R. Mukundan, M.D. Campbell, W.E. Zackert, V.C. Daniel, K.F. Baid, I.A. Baid, and L.J. Roberts, Free Radical-Induced Generation of Isoprostanes in vivo. Evidence for the Formation of D-Ring and E-Ring Isoprostanes, J. Biol. Chem. 269:4317–4326 (1994).

146. Halliwell, B., Oxidative Stress, Nutrition and Health. Experimental Strategies for Optimization of Nutritional Antioxidant Intake in Humans, Free Radical Res. 25:57–74 (1996).

147. Halliwell, B., Biochemical Mechanisms Accounting for the Toxic Action of Oxygen on Living Organisms. The Key Role of Superoxide Dismutase, Cell Biol. Int. Rep. 2:113–118 (1978).

148. Ramotar, D., and B. Demple, Enzymes That Repair Oxidative Damage to DNA, in DNA and Free Radicals, edited by B. Halliwell and O.I. Aruoma, Ellis Horwood, London, 1993, pp. 166–191.

149. Dean, R.T., J.V. Hunt, A.J. Grant, Y. Yamamoto, and E. Niki, Free Radical Damage to Proteins: The Influence of the Relative Localization of Radical Generation, Antioxidants and Tar-
153. Wells-Knecht, M.C., T.G. Huggins, D.G. Dyer, S.R. Thorpe, and J.W. Baynes, Oxidized Amino Acids in Lens Proteins with Age. Measurement of o-Tyrosine and Dityrosine in the Aging Human Lens, *J. Biol. Chem.* 268:12348–12352 (1993).

154. Reznick, A.Z., and L. Packer, Oxidative Damage to Proteins: Spectrophotometric Method for Carboxyl Assay, *Methods Enzymol.* 233:357–363 (1994).

155. Amici, A., R.L. Levine, L. Tsai, and E.R Stadtman, Conversion of Amino Acid Residues in Proteins and Amino Acid Homopolymers to Carboxyl Derivatives by Metal-Catalyzed Oxidation Reactions, *J. Biol. Chem.* 264:3341–3346 (1989).

156. Cao, G., and R.G. Cutler, Protein Oxidation and Aging. Difficulties in Measuring Reactive Protein Carboxyls in Tissues Using 2,4-Dinitrophenylhydrazine, *Arch. Biochem. Biophys.* 320:106–114 (1995).

157. Lytras, L., P.J. Shaw, P.J. Evans, and B. Halliwell, Oxidative Damage and Motor Neurone Disease. Difficulties in the Measurement of Protein Carboxyls in Human Brain Tissue, *Free Radical Res.* 24:397–406 (1996).

158. Levine, R.L., J.A. Williams, E.R. Stadtman, and E. Shacter, Carboxyl Assays for Determination of Oxidatively Modified Proteins, *Methods Enzymol.* 233:346–357 (1994).

159. Keller, J., N.C. Halms, J.A. Hinson, and N.R. Pumford, Immunochemical Detection of Oxidized Proteins, *Chem. Res. Toxicol.* 6:430–433 (1993).

160. Oliver, C.N., B.A. Ahn, E.J. Moerman, S. Goldstein, and E.R. Stadtman, Age-Related Changes in Oxidized Proteins, *J. Biol. Chem.* 262:5488–5491 (1987).

161. Ambe, K.S., and A.L. Tappel, Oxidative Damage to Amino Acids, Peptides and Proteins by Radiation, *J. Food Sci.* 26:448–451 (1962).

162. Dean, R.T., S. Fu, R. Stocker, and M.J. Davies, Biochemistry and Pathology of Radical Mediated Protein Oxidation, *Biochem. J.* 324:1–18 (1997).

163. S. Fu, S., R.T. Dean, and M.J. Davies, Molecular Aspects of Free Radical Damage to Proteins, in *Molecular Biology of Free Radicals in Human Diseases*, edited by O.I. Aruoma and B. Halliwell, OICA International, Saint Lucia, 1998, pp. 29–56.

164. Aruoma, O.I., Extracts as Antioxidant Prophylactic Agents, *INFORM* 8:1236–1242 (1997).